<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228237</url>
  </required_header>
  <id_info>
    <org_study_id>CPFS/Reg18.01</org_study_id>
    <nct_id>NCT04228237</nct_id>
  </id_info>
  <brief_title>LUng CAncer focuS - Long-term Monitoring of Bronchogenic Carcinoma Patients (LUCAS)</brief_title>
  <acronym>LUCAS</acronym>
  <official_title>LUng CAncer focuS - Long Term Non-interventional Monitoring of Diagnostic and Treatment Patterns in Patients With Bronchogenic Carcinoma (LUCAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ceska Lekarska Spolecnost Jana Evangelisty Purkyne z.s.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OAKS Consulting s.r.o.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ceska Lekarska Spolecnost Jana Evangelisty Purkyne z.s.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term non-interventional monitoring of diagnostics and treatment patterns in newly
      diagnosed patients in selected pneumology centers in Czech republic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diagnosis, treatment and care of patients with bronchogenic carcinoma (BCA) is, as with most
      other oncological diseases, a complex multidisciplinary process. Due to the lack of
      information on the speed and success of the initial diagnosis, the use of the necessary
      laboratory techniques, and the individual therapeutic steps leading to cure or medical
      failure, the Czech Pneumological and Phtizeology Society (CPPS) decided to carry out
      long-term non-interventional monitoring of newly diagnosed patients.

      This monitoring is non-interventional, so the usual diagnostic and therapeutic procedures
      will be used according to the decision of the physician. All patients with bronchogenic
      carcinoma diagnosed from June 1, 2018 will be enrolled with up to 60 months of follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>60 months of follow-up</time_frame>
    <description>Time from randomization until death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>any treatment during 60 months of follow-up</time_frame>
    <description>Time from randomization until disease progression or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to treatment discontinuation (TTD)</measure>
    <time_frame>any treatment during 60 months of follow-up</time_frame>
    <description>time from starting a medication until treatment discontinuation or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment (TTNT)</measure>
    <time_frame>60 months of follow-up</time_frame>
    <description>Time from end of primary treatment to institution of next therapy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2300</enrollment>
  <condition>Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        all newly diagnosed patients in participating pulmonology centers
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - clinical diagnosis of lung cancer (C34 in MKN classification)

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martina Vasakova, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomayer hospital Prague</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jana Alahakoon</last_name>
    <phone>+420602350988</phone>
    <email>jana.alahakoon@oaks.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaroslav Duba</last_name>
    <phone>+420606613224</phone>
    <email>jaroslav.duba@oaks.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Skrickova, Prof.</last_name>
      <phone>+420602726490</phone>
      <email>skrickova.jana@fnbrno.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty hospital Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Koblizek, Ass.Prof.</last_name>
      <phone>+420495834772</phone>
      <email>vladimir.koblizek@fnhk.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vitezslav Kolek, Prof.</last_name>
      <phone>+420588443560</phone>
      <email>vitezslav.kolek@fnol.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty hospital Plzen</name>
      <address>
        <city>Plzen</city>
        <zip>30599</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milos Pesek, Prof.</last_name>
      <phone>+420377402238</phone>
      <email>pesek@fnplzen.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomayer hospital</name>
      <address>
        <city>Prague</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Vasakova, Prof.</last_name>
      <phone>+420261082372</phone>
      <email>martina.vasakova@ftn.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty hospital Motol</name>
      <address>
        <city>Praha 5</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miloslav Marel, Prof.</last_name>
      <phone>+420224436659</phone>
      <email>miloslav.marel@fnmotol.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Bulovce</name>
      <address>
        <city>Praha 8</city>
        <state>Česká Republika</state>
        <zip>18000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Opalka, MD</last_name>
      <phone>+420266082267</phone>
      <email>petr.opalka@bulovka.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>bronchogenic carcinoma</keyword>
  <keyword>diagnosis</keyword>
  <keyword>treatment</keyword>
  <keyword>non-interventional</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Bronchogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

